Why has Goldman Sachs just upgraded CSL shares?

This biotech giant could be in the buy zone according to a leading broker.

| More on:
A smiling businessman in the city looks at his phone and punches the air in celebration of good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Now could be the time to snap up CSL Limited (ASX: CSL) shares.

That's the view of analysts at Goldman Sachs, which believe that now is a "compelling entry point after [a] multiple de-rate."

Why are CSL shares a buy?

Goldman has been looking at the biotherapeutics giant's outlook and believes it is entering a capital-efficient growth period. In light of this, the broker is forecasting major improvements in its returns between now and FY 2027. It said:

CSL is now entering a period of more capital-efficient growth, driving a sharp improvement in our ROIC forecast (+460bps by FY27E). This positive inflection also coincides with a period of historically-high earnings growth (+14% CAGR FY23-27E), which serves to amplify those incremental returns to shareholders.

Goldman also highlights that despite the above, CSL shares are trading at a significant discount to historical levels. Though, it suspects that if its predictions come true, this discount won't last long. It adds:

Although CSL's valuation has historically correlated closely with our measure of forward returns, this relationship broke down through FY22-23 as the NTM P/E multiple de-rated more quickly than expected (from c.46x in Jun-21 to c.23x in Oct-23). However, the forward profile is now materially stronger, and we expect reported improvements in margins/returns through the upcoming periods to once again drive a re-rating in the shares.

Major upside potential

According to the note, the broker has upgraded CSL's shares to a buy rating with a $309.00 price target.

Based on its current share price, this implies a potential upside of 22% for investors over the next 12 months.

All in all, Goldman appears to believe this could be a great time for investors to snap up the shares of one of Australia's highest-quality companies.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »